Volume 121, Issue 3 , Pages 614-619, March 2008
Advances in pediatric asthma in 2007
This year's summary focuses on recent advances in pediatric asthma as reported in 2007 publications in the Journal. This past year, new National Asthma Education and Prevention Program asthma guidelines were released with a special emphasis on new information in pediatric asthma. Journal theme issues in 2007 included the revised National Asthma Education and Prevention Program asthma guidelines, the accomplishments of the National Institutes of Health asthma networks, and focused discussions on environmental allergens, neutrophils, eosinophils, T cells, and epithelial cells, all of which affect pediatric asthma. The new asthma guidelines emphasize several key terms including severity, control, impairment, risk, and responsiveness that are relevant for advancing the care of children with asthma. This review highlights Journal articles that relate to these guideline topics.
Key words: Asthma, asthma control, asthma impairment, asthma risk, asthma severity, early intervention in asthma, biomarkers, therapeutics
Abbreviations used: ACRN, Asthma Clinical Research Network, CAMP, Childhood Asthma Management Program, CARE, Childhood Asthma Research and Education Network, ICS, Inhaled corticosteroid, LABA, Long-acting β-adrenergic agonist, LTRA, Leukotriene receptor antagonist, NAEPP, National Asthma Education and Prevention Program, NHLBI, National Heart, Lung, and Blood Institute, PACT, Pediatric Asthma Controller Trial
Supported in part by Public Health Services Research Grants HR-16048, HL64288, HL51834, AI-25496, HL081335, and HL075416; General Clinical Research Center Grant 5 MO1 RR00051; and the Colorado Cancer, Cardiovascular and Pulmonary Disease Program.
Disclosure of potential conflict of interest: S. Szefler has consulting arrangements with AstraZeneca, GlaxoSmithKline, Aventis, Genentech, and Merck and has received research support from the National Institutes of Health, the National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases, and Ross Pharmaceuticals.
PII: S0091-6749(07)02378-0
doi:10.1016/j.jaci.2007.11.033
© 2008 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 121, Issue 3 , Pages 614-619, March 2008

